227 related articles for article (PubMed ID: 30357946)
1. PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Blazquez R; Wlochowitz D; Wolff A; Seitz S; Wachter A; Perera-Bel J; Bleckmann A; Beißbarth T; Salinas G; Riemenschneider MJ; Proescholdt M; Evert M; Utpatel K; Siam L; Schatlo B; Balkenhol M; Stadelmann C; Schildhaus HU; Korf U; Reinz E; Wiemann S; Vollmer E; Schulz M; Ritter U; Hanisch UK; Pukrop T
Glia; 2018 Nov; 66(11):2438-2455. PubMed ID: 30357946
[TBL] [Abstract][Full Text] [Related]
2. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
3. Buparlisib in breast cancer.
Sirohi B; Rastogi S; Dawood S
Future Oncol; 2015; 11(10):1463-70. PubMed ID: 25963424
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Estévez LG; García E; Hidalgo M
Clin Transl Oncol; 2016 Jun; 18(6):541-9. PubMed ID: 26510854
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Zhang WL; Ma WJ; Chen S; Wu XZ; Zhang HR; Zhang JH
Zhonghua Zhong Liu Za Zhi; 2016 Aug; 38(8):578-88. PubMed ID: 27531477
[TBL] [Abstract][Full Text] [Related]
9. Long-term characterization of activated microglia/macrophages facilitating the development of experimental brain metastasis through intravital microscopic imaging.
Qiao S; Qian Y; Xu G; Luo Q; Zhang Z
J Neuroinflammation; 2019 Jan; 16(1):4. PubMed ID: 30616691
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of buparlisib in treating breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Opin Pharmacother; 2017 Dec; 18(18):2007-2016. PubMed ID: 29169282
[TBL] [Abstract][Full Text] [Related]
11. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
[TBL] [Abstract][Full Text] [Related]
12. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
[TBL] [Abstract][Full Text] [Related]
13. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer.
Peddi PF; Hurvitz SA
J Neurooncol; 2014 Mar; 117(1):7-13. PubMed ID: 24469856
[TBL] [Abstract][Full Text] [Related]
14. Immune Microenvironment of Brain Metastases-Are Microglia and Other Brain Macrophages Little Helpers?
You H; Baluszek S; Kaminska B
Front Immunol; 2019; 10():1941. PubMed ID: 31481958
[TBL] [Abstract][Full Text] [Related]
15. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way.
Pukrop T; Dehghani F; Chuang HN; Lohaus R; Bayanga K; Heermann S; Regen T; Van Rossum D; Klemm F; Schulz M; Siam L; Hoffmann A; Trümper L; Stadelmann C; Bechmann I; Hanisch UK; Binder C
Glia; 2010 Sep; 58(12):1477-89. PubMed ID: 20549749
[TBL] [Abstract][Full Text] [Related]
16. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
17. Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury.
Wang P; He Y; Li D; Han R; Liu G; Kong D; Hao J
J Neuroinflammation; 2016 Aug; 13(1):192. PubMed ID: 27549161
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid a differentially activates microglia and astrocytes via the PI3K pathway.
Yu Y; Liu J; Li SQ; Peng L; Ye RD
J Alzheimers Dis; 2014; 38(1):133-44. PubMed ID: 23948927
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
20. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
